The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Outcome of Patients Treated for Relapsed or Refractory Acute Lymphoblastic Leukemia: A Therapeutic Advances in Childhood Leukemia Consortium Study
Open accessAbstract
Purpose: Despite improvements in treatment, approximately 20% of patients with acute lymphoblastic leukemia (ALL) experience relapse and do poorly. The Therapeutic Advances in Childhood Leukemia (TACL) Consortium was assembled to assess novel drugs for children with resistant leukemia. We hypothesize that novel agents and combinations that fail to improve baseline complete remission rates in comparable populations are unlikely to contribute to better outcomes and should be abandoned. We sought to define response rates and disease-free survival (DFS) rates in patients treated at TACL institutions, which could serve as a comparator for future studies. Patients and Methods: We performed a retrospective cohort review of patients with relapsed and refractory ALL previously treated at TACL institutions between the years of 1995 and 2004. Data regarding initial and relapsed disease characteristics, disease response, and survival were collected and compared with those of published reports. Results: Complete remission (CR) rates (mean ± SE) were 83% ± 4% for early first marrow relapse, 93% ± 3% for late first marrow relapse, 44% ± 5% for second marrow relapse, and 27% ± 6% for third marrow relapse. Five-year DFS rates in CR2 and CR3 were 27% ± 4% and 15% ± 7% respectively. Conclusion: We generally confirm a 40% CR rate for second and subsequent relapse, but our remission rate for early first relapse seems better than that reported in the literature (83% v approximately 70%). Our data may allow useful modeling of an expected remission rate for any population of patients who experience relapse.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cox, D. R., & Oakes, D. (2018) · Chapman & Hall/CRC eBooks · doi:10.1201/9781315137438 · Cited by 6,234
(2008) · The Concise Encyclopedia of Statistics · doi:10.1007/978-0-387-32833-1_5 · Cited by 2,670
Nguyen, K., Devidas, M., Cheng, S.-C., La, M., Raetz, E. A., Carroll, W. L., Winick, N. J., Hunger, S. P., Gaynon, P. S., Loh, M. L., et al. (2008) · Leukemia · doi:10.1038/leu.2008.251 · Cited by 582
Self-citationThe pediatric preclinical testing program: Description of models and early testing results
Houghton, P. J., Morton, C. L., Tucker, C., Payne, D., Favours, E., Cole, C., Gorlick, R., Kolb, E. A., Zhang, W., Lock, R., et al. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.21078 · Cited by 480
Raetz, E. A., Borowitz, M. J., Devidas, M., Linda, S. B., Hunger, S. P., Winick, N. J., Camitta, B. M., Gaynon, P. S., & Carroll, W. L. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.1414 · Cited by 222
Self-citationRaetz, E. A., Cairo, M. S., Borowitz, M. J., Blaney, S. M., Krailo, M. D., Leil, T. A., Reid, J. M., Goldenberg, D. M., Wegener, W. A., Carroll, W. L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.3528 · Cited by 208
Self-citationFifty Years of Studies of the Biology and Therapy of Childhood Leukemia
Kersey, J. H. (1997) · Blood · doi:10.1182/blood.v90.11.4243.4243_4243_4251 · Cited by 180
Eapen, M. (2006) · Blood · doi:10.1182/blood-2005-12-4942 · Cited by 166
Long‐term follow‐up of relapsed childhood acute lymphoblastic leukaemia
Chessells, J. M., Veys, P. A., Kempski, H. M., et al. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04584.x · Cited by 155
Malempati, S., Gaynon, P. S., Sather, H. N., La, M., & Stork, L. C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.7508 · Cited by 107
Self-citationBone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia
Rivera, G. K., Zhou, Y., Hancock, M. L., Gajjar, A. J., Rubnitz, J. E., Ribeiro, R. C., Sandlund, J. T., Hudson, M. M., Relling, M. V., Evans, W. E., et al. (2004) · Cancer · doi:10.1002/cncr.20743 · Cited by 82
Reismüller, B., Attarbaschi, A., Peters, C., Dworzak, M. N., Pötschger, U., Urban, C. E., Fink, F., Meister, B., Schmitt, K., Dieckmann, K. U., et al. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07499.x · Cited by 78
Cited by
von Stackelberg, A., Locatelli, F., Zugmaier, G., Handgretinger, R., Trippett, T. M., Rizzari, C., Bader, P., O’Brien, M. M., Brethon, B., Bhojwani, D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3301 · Cited by 614
Self-citationRelapsed childhood acute lymphoblastic leukaemia
Bhojwani, D., & Pui, C.-H. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70580-6 · Cited by 414
Parker, C., Waters, R., Leighton, C., Hancock, J., Sutton, R., Moorman, A. V., Ancliff, P., Morgan, M., Masurekar, A., Goulden, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)62002-8 · Cited by 330
Pullarkat, V. A., Lacayo, N. J., Jabbour, E., Rubnitz, J. E., Bajel, A., Laetsch, T. W., Leonard, J., Colace, S. I., Khaw, S. L., Fleming, S. A., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1465 · Cited by 302
O'Leary, M. C., Lu, X., Huang, Y., Lin, X., Mahmood, I., Przepiorka, D., Gavin, D., Lee, S., Liu, K., George, B., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2035 · Cited by 298
Metadata
- Authors
- Ko, R. H., Ji, L., Barnette, P., Bostrom, B., Hutchinson, R., Raetz, E., Seibel, N. L., Twist, C. J., Eckroth, E., Sposto, R., Gaynon, P. S., & Loh, M. L.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-02-01
- Volume
- 28
- Issue
- 4
- Pages
- 648-654
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2037522752
- Cited by
- 281
- References
- 12
- FWCI
- 11.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.